Alacrity Biosciences Inc.
This article was originally published in Start Up
Executive Summary
Alacrity's strategy is to in-license products that have particular promise in key ophthalmic indications, such as dry eye, glaucoma, and retinal disease. According to its founders, its specialty is recognizing the potential of these products, licensing them in, and taking them through the development process--formulation, preclinical toxicology, clinical development--everything that's needed to take a drug to the FDA and other regulatory agencies.
You may also be interested in...
The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs
Over the past few years's there's been no shortage of venture capital investments in companies developing potential treatments for diseases of the eye. Still, investors continue to find entrepreneurs with innovative new approaches to treat age-related macular degeneration, glaucoma and other vision-imparing diseases.
Start-Up Previews (09/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Eyes Still Have It," features profiles of Alacrity Biosciences, Eyeon Therapeutics, Mobius Therapeutics and OcuCure Therapeutics. Plus these Start-Ups Across Health Care: CyberHeart, GlycoVaxyn, TheraCardia and Vicus Therapeutics.
Start-Up Previews (09/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Eyes Still Have It," features profiles of Alacrity Biosciences, Eyeon Therapeutics, Mobius Therapeutics and OcuCure Therapeutics. Plus these Start-Ups Across Health Care: CyberHeart, GlycoVaxyn, TheraCardia and Vicus Therapeutics.